Last update July 15, 2022
Very Low Risk
An antiprotozoal used in the treatment of cryptosporidiosis, giardiasis, intestinal amebiasis, blastocystosis, cutaneous leishmaniasis and microsporidiosis. Oral administration twice a day for 3 days.
Its pharmacokinetic data - extremely high percentage of protein binding (MK 2014, FDA 2005) and short half-life (Stocks 1996) - explain the negligible transfer to breastmilk observed. (Hadad 2012)
Its use is authorized in children from one year of age. (Committee 2015, FDA 2005)
Possible side effects are not frequent or serious (abdominal pain, diarrhea, vomiting, headache).
Several experts consider its use to be safe during breastfeeding. (LsctMed, Briggs 2015)
We do not have alternatives for P01AX11 since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.